Efficacy of eculizumab in refractory life‐threatening warm autoimmune hemolytic anemia associated with chronic myelomonocytic leukemia

Efficacy of eculizumab in refractory life‐threatening warm autoimmune hemolytic anemia associated with chronic myelomonocytic leukemia

Abstract Eculizumab may be considered as an emergency therapeutic option in refractory life‐threatening warm autoimmune hemolytic anemia especially if direct antiglobulin test is positive for both IgG and C3d and after failure of all conventional treatments.

Bibliographic Details
Main Authors: Anne‐Cécile Gauchy, Maxime Hentzien, Alain Wynckel, Victoire de Marcellus, Cyrielle Rodier, Alain Delmer, Anne Quinquenel
Format: Article
Language:English
Published: Wiley 2020-12-01
Series:Clinical Case Reports
Subjects:
chronic myelomonocytic leukemia
eculizumab
warm autoimmune hemolytic anemia
Online Access:https://doi.org/10.1002/ccr3.3250
id doaj-e420a5d6606a4e9ba2691a55bc8c2aed
record_format Article
spelling doaj-e420a5d6606a4e9ba2691a55bc8c2aed2021-08-02T06:23:37ZengWileyClinical Case Reports2050-09042020-12-018122641264410.1002/ccr3.3250Efficacy of eculizumab in refractory life‐threatening warm autoimmune hemolytic anemia associated with chronic myelomonocytic leukemiaAnne‐Cécile Gauchy0Maxime Hentzien1Alain Wynckel2Victoire de Marcellus3Cyrielle Rodier4Alain Delmer5Anne Quinquenel6Service d'Hématologie Clinique Hôpital Robert Debré Centre Hospitalier Universitaire Reims FranceUFR Médecine Université Reims Champagne‐Ardenne Reims FranceService de Néphrologie Hôpital Robert Debré Centre Hospitalier Universitaire Reims FranceService d'Hématologie Clinique Hôpital Robert Debré Centre Hospitalier Universitaire Reims FranceService d'Hématologie Clinique Hôpital Robert Debré Centre Hospitalier Universitaire Reims FranceService d'Hématologie Clinique Hôpital Robert Debré Centre Hospitalier Universitaire Reims FranceService d'Hématologie Clinique Hôpital Robert Debré Centre Hospitalier Universitaire Reims FranceAbstract Eculizumab may be considered as an emergency therapeutic option in refractory life‐threatening warm autoimmune hemolytic anemia especially if direct antiglobulin test is positive for both IgG and C3d and after failure of all conventional treatments.https://doi.org/10.1002/ccr3.3250chronic myelomonocytic leukemiaeculizumabwarm autoimmune hemolytic anemia
collection DOAJ
language English
format Article
sources DOAJ
author Anne‐Cécile Gauchy
Maxime Hentzien
Alain Wynckel
Victoire de Marcellus
Cyrielle Rodier
Alain Delmer
Anne Quinquenel
spellingShingle Anne‐Cécile Gauchy
Maxime Hentzien
Alain Wynckel
Victoire de Marcellus
Cyrielle Rodier
Alain Delmer
Anne Quinquenel
Efficacy of eculizumab in refractory life‐threatening warm autoimmune hemolytic anemia associated with chronic myelomonocytic leukemia
Clinical Case Reports
chronic myelomonocytic leukemia
eculizumab
warm autoimmune hemolytic anemia
author_facet Anne‐Cécile Gauchy
Maxime Hentzien
Alain Wynckel
Victoire de Marcellus
Cyrielle Rodier
Alain Delmer
Anne Quinquenel
author_sort Anne‐Cécile Gauchy
title Efficacy of eculizumab in refractory life‐threatening warm autoimmune hemolytic anemia associated with chronic myelomonocytic leukemia
title_short Efficacy of eculizumab in refractory life‐threatening warm autoimmune hemolytic anemia associated with chronic myelomonocytic leukemia
title_full Efficacy of eculizumab in refractory life‐threatening warm autoimmune hemolytic anemia associated with chronic myelomonocytic leukemia
title_fullStr Efficacy of eculizumab in refractory life‐threatening warm autoimmune hemolytic anemia associated with chronic myelomonocytic leukemia
title_full_unstemmed Efficacy of eculizumab in refractory life‐threatening warm autoimmune hemolytic anemia associated with chronic myelomonocytic leukemia
title_sort efficacy of eculizumab in refractory life‐threatening warm autoimmune hemolytic anemia associated with chronic myelomonocytic leukemia
publisher Wiley
series Clinical Case Reports
issn 2050-0904
publishDate 2020-12-01
description Abstract Eculizumab may be considered as an emergency therapeutic option in refractory life‐threatening warm autoimmune hemolytic anemia especially if direct antiglobulin test is positive for both IgG and C3d and after failure of all conventional treatments.
topic chronic myelomonocytic leukemia
eculizumab
warm autoimmune hemolytic anemia
url https://doi.org/10.1002/ccr3.3250
work_keys_str_mv AT annececilegauchy efficacyofeculizumabinrefractorylifethreateningwarmautoimmunehemolyticanemiaassociatedwithchronicmyelomonocyticleukemia
AT maximehentzien efficacyofeculizumabinrefractorylifethreateningwarmautoimmunehemolyticanemiaassociatedwithchronicmyelomonocyticleukemia
AT alainwynckel efficacyofeculizumabinrefractorylifethreateningwarmautoimmunehemolyticanemiaassociatedwithchronicmyelomonocyticleukemia
AT victoiredemarcellus efficacyofeculizumabinrefractorylifethreateningwarmautoimmunehemolyticanemiaassociatedwithchronicmyelomonocyticleukemia
AT cyriellerodier efficacyofeculizumabinrefractorylifethreateningwarmautoimmunehemolyticanemiaassociatedwithchronicmyelomonocyticleukemia
AT alaindelmer efficacyofeculizumabinrefractorylifethreateningwarmautoimmunehemolyticanemiaassociatedwithchronicmyelomonocyticleukemia
AT annequinquenel efficacyofeculizumabinrefractorylifethreateningwarmautoimmunehemolyticanemiaassociatedwithchronicmyelomonocyticleukemia
_version_ 1721240345091506176

Similar Items